210 related articles for article (PubMed ID: 32962686)
21. Immunotherapeutic Significance of a Prognostic Alternative Splicing Signature in Bladder Cancer.
Chen J; Liao Y; Li R; Luo M; Wu G; Tan R; Xiao Z
Technol Cancer Res Treat; 2022; 21():15330338221090093. PubMed ID: 35509211
[No Abstract] [Full Text] [Related]
22. Development of a Nomogram With Alternative Splicing Signatures for Predicting the Prognosis of Glioblastoma: A Study Based on Large-Scale Sequencing Data.
Wang Z; Gao L; Guo X; Feng C; Lian W; Deng K; Xing B
Front Oncol; 2020; 10():1257. PubMed ID: 32793502
[No Abstract] [Full Text] [Related]
23. Prognostic alternative splicing signature reveals the landscape of immune infiltration in Pancreatic Cancer.
Wang L; Bi J; Li X; Wei M; He M; Zhao L
J Cancer; 2020; 11(22):6530-6544. PubMed ID: 33046974
[No Abstract] [Full Text] [Related]
24. Development of a nomogram for prognostic prediction of lower-grade glioma based on alternative splicing signatures.
Wang Y; Wang Z; Zhao B; Chen W; Wang Y; Ma W
Cancer Med; 2020 Dec; 9(24):9266-9281. PubMed ID: 33047900
[TBL] [Abstract][Full Text] [Related]
25. Systematic profiling of a novel prognostic alternative splicing signature in hepatocellular carcinoma.
Zhang D; Duan Y; Wang Z; Lin J
Oncol Rep; 2019 Dec; 42(6):2450-2472. PubMed ID: 31578577
[TBL] [Abstract][Full Text] [Related]
26. Transcriptome profiling reveals an integrated mRNA-lncRNA signature with predictive value of early relapse in colon cancer.
Dai W; Feng Y; Mo S; Xiang W; Li Q; Wang R; Xu Y; Cai G
Carcinogenesis; 2018 Oct; 39(10):1235-1244. PubMed ID: 29982331
[TBL] [Abstract][Full Text] [Related]
27. An Integrated miRNA-lncRNA Signature Predicts the Survival of Stage II Colon Cancer.
Wang XJ; Zeng B; Lin S; Chen M; Chi P
Ann Clin Lab Sci; 2019 Nov; 49(6):730-739. PubMed ID: 31882423
[TBL] [Abstract][Full Text] [Related]
28. Systematic Identification of Survival-Associated Alternative Splicing Events in Kidney Renal Clear Cell Carcinoma.
Wei Y; Zhang Z; Peng R; Sun Y; Zhang L; Liu H
Comput Math Methods Med; 2021; 2021():5576933. PubMed ID: 33959190
[TBL] [Abstract][Full Text] [Related]
29. Genome-wide profiling of alternative splicing in glioblastoma and their clinical value.
Li Y; Guo D
BMC Cancer; 2021 Aug; 21(1):958. PubMed ID: 34445990
[TBL] [Abstract][Full Text] [Related]
30. Novel Insights Into Triple-Negative Breast Cancer Prognosis by Comprehensive Characterization of Aberrant Alternative Splicing.
Gong S; Song Z; Spezia-Lindner D; Meng F; Ruan T; Ying G; Lai C; Wu Q; Liang Y
Front Genet; 2020; 11():534. PubMed ID: 32595697
[TBL] [Abstract][Full Text] [Related]
31. Systematic analysis of alternative splicing signature unveils prognostic predictor for kidney renal clear cell carcinoma.
Song J; Liu YD; Su J; Yuan D; Sun F; Zhu J
J Cell Physiol; 2019 Dec; 234(12):22753-22764. PubMed ID: 31140607
[TBL] [Abstract][Full Text] [Related]
32. Alternative Splicing Events as Indicators for the Prognosis of Uveal Melanoma.
Wan Q; Sang X; Jin L; Wang Z
Genes (Basel); 2020 Feb; 11(2):. PubMed ID: 32098099
[TBL] [Abstract][Full Text] [Related]
33. Identification of Prognostic Alternative Splicing Signature in Breast Carcinoma.
Zhang D; Duan Y; Cun J; Yang Q
Front Genet; 2019; 10():278. PubMed ID: 30984247
[TBL] [Abstract][Full Text] [Related]
34. Identification of novel prognostic alternative splicing signature in papillary renal cell carcinoma.
Duan Y; Zhang D
J Cell Biochem; 2020 Jan; 121(1):672-689. PubMed ID: 31407370
[TBL] [Abstract][Full Text] [Related]
35. Alternative Splicing Events and Splicing Factors Are Prognostic in Adrenocortical Carcinoma.
Lv J; He Y; Li L; Wang Z
Front Genet; 2020; 11():918. PubMed ID: 33101358
[TBL] [Abstract][Full Text] [Related]
36. Comprehensive Analysis of Prognostic Alternative Splicing Signature Reveals Recurrence Predictor for Papillary Thyroid Cancer.
Liu M; Khushbu RA; Chen P; Hu HY; Tang N; Ou-Yang DJ; Wei B; Zhao YX; Huang P; Chang S
Front Oncol; 2021; 11():705929. PubMed ID: 34722250
[TBL] [Abstract][Full Text] [Related]
37. Identification of survival-related alternative splicing signatures in acute myeloid leukemia.
Zhang B; Yang L; Wang X; Fu D
Biosci Rep; 2021 Jul; 41(7):. PubMed ID: 34212178
[TBL] [Abstract][Full Text] [Related]
38. Determining the prognostic significance of alternative splicing events in soft tissue sarcoma using data from The Cancer Genome Atlas.
Yang X; Huang WT; He RQ; Ma J; Lin P; Xie ZC; Ma FC; Chen G
J Transl Med; 2019 Aug; 17(1):283. PubMed ID: 31443718
[TBL] [Abstract][Full Text] [Related]
39. Prognostic risk assessment model for alternative splicing events and splicing factors in malignant pleural mesothelioma.
Jiang Y; Zhang C; Chen Y; Zhao S; He Y; He J
Cancer Med; 2023 Feb; 12(4):4895-4906. PubMed ID: 36031798
[TBL] [Abstract][Full Text] [Related]
40. Identification of a nomogram based on long non-coding RNA to improve prognosis prediction of esophageal squamous cell carcinoma.
Li W; Liu J; Zhao H
Aging (Albany NY); 2020 Jan; 12(2):1512-1526. PubMed ID: 31978896
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]